Heparin Market Analysis Europe, North America, Asia, Rest of World (ROW) - US, UK, Germany, France, China - Size and Forecast 2024-2028

Heparin Market Forecast 2024-2028

The Global Heparin Market size is estimated to grow by USD 3.34 billion at a CAGR of 7.22% between 2023 and 2028. The increasing prevalence of coagulation disorders, such as hemophilia and thrombophilia, is driving the demand for products that can help manage these conditions, including anticoagulants and clotting factors. The growing prevalence of chronic conditions, such as cardiovascular diseases and cancer, is also contributing to the demand for these products, as these conditions can increase the risk of coagulation disorders. Additionally, the reintroduction of alternative sources to produce heparin, a commonly used anticoagulant, is providing more options for patients and healthcare providers, which could further drive the market. Overall, these factors are contributing to the growth of the market for products related to coagulation disorders.

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.

What will be the Size of the Heparin Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation 

This report extensively covers market segmentation by product (low-molecular-weight heparin and others), route of administration (subcutaneous injection and intravenous infusion), and geography (Europe, North America, Asia, and the Rest of World (ROW). 

By Product 

The low-molecular-weight heparin segment is estimated to witness significant growth during the forecast period. The segment acts by inhibiting the coagulation mechanism. In addition, it converts fibrinogen into fibrin by the activity of thrombin. Furthermore, this inhibits coagulation by activating antithrombin III. Thus, it prevents the activation of the Xa factor, and prothrombin is not converted to thrombin, thus not converting fibrinogen into fibrin for the formation of a clot.

Get a glance at the market contribution of various segments Download PDF Sample

The low-molecular-weight heparin segment was the largest segment and was valued at USD 4.86 billion in 2018. Moreover, this is derived from unfractionated heparin by the depolymerization of longer chains of heparin into shorter chains by chemical or enzymatic methods. In addition, these short strands make them last longer and act more certainly in an individual body than unfractionated heparin. Furthermore, they do not require regular blood monitoring as necessary for unfractionated heparin treatment. Hence, such factors are fuelling the growth of this segment which in turn will drive the market growth during the forecast period.

By Route Of Administration 

Subcutaneous administration is becoming more proficient at administering a wide variety of therapeutics due to the recent advances in formulation and delivery technologies. In addition, this route of administration enables therapeutics to be self-administered by patients using a variety of different drug delivery systems. Moreover, subcutaneous administration provides a reduction in medical fixed costs because it facilitates patient self-administration at home. In addition, this is given by deep subcutaneous injection with a fine (25 to 26 gauge) needle to minimize tissue trauma. Furthermore, a concentrated solution of heparin sodium is recommended for subcutaneous administration. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.

Intravenous infusion

Heparin is mainly given by intravenous injection or infusion. In this segment, this is directly administered into the vein using a needle or a tube. In addition, this route of administration is used because of the control it provides over the dosage. Moreover, this route of administration has the desirable pharmacokinetic and pharmacodynamic features. Furthermore, intravenous solutions with heparin sodium, which is derived from porcine intestinal mucosa, are sterile and nonpyrogenic fluids for intravenous administration. In addition, unfractionated can also be administered as an intravenous injection. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.

By Region

For more insights about the market share of various regions Download PDF Sample now!

Europe is estimated to contribute 34% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period.  UK, Germany, and France are some of the main countries contributing to the market in Europe. In addition, the regional market is driven by the increasing prevalence of obesity, smoking, and the high consumption of alcohol. Moreover, another factor driving the growth of the market in Europe is the increasing number of surgeries in the region. For instance, during and after surgeries, this is considered the first-line therapy to treat thrombosis. The estimated annual incidence of venous thromboembolism in Europe ranges from 0.10% to 0.18% of individuals per year. Furthermore, this increasing prevalence of deep vein thrombosis and pulmonary embolism has fueled the adoption of these in the region. Hence, such factors are driving the market growth in Europe during the forecast period.

Buy Full Report Now

Key Heparin Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Aspen Pharmacare Holdings Ltd: The company offers Heparin under brands such as Diprivan, Emla, Ultiva, and others.

• B.Braun SE
• Baxter International Inc.
• Dr Reddys Laboratories Ltd.
• Eisai Co. Ltd.
• Fresenius SE and Co. KGaA
• Hebei Changshan Biochemical
• Hikma Pharmaceuticals Plc
• Laboratorios Farmaceuticos ROVI S A
• LEO Pharma AS
• Nanjing Kingfriend Biochemical
• Nichi Iko Pharmaceutical Co. Ltd.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Shanghai Fosun Pharmaceutical Group Co. Ltd.
• Shenzhen Techdow Pharmaceutical
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Opocrin SpA

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Market Drivers

One of the key factors driving the market growth is the increasing prevalence of coagulation disorders. The prevalence of different coagulation disorders, including Von Willebrand disease, hemophilia, deep venous thrombosis, hypercoagulable states, and clotting factor deficiencies, is increasing significantly across the globe. For instance, according to the data published by the CDC in July 2020, nearly 400 babies are born with hemophilia A every year in the US.

Moreover, according to the data stated by the CDC in February 2020, nearly 900,000 people in the US are affected by venous thromboembolism, also known as DVT/PE, every year. Therefore, the increasing prevalence of various coagulation diseases among people around the world requires continuous monitoring for further medical interventions. Hence, such factors are driving the market growth during the forecast period.

Significant Market Trends

A key factor shaping the market growth is the advent of biosimilar low-molecular-weight heparin. These products are essentially animal-derived products developed by the chemical depolymerization of unfractionated heparin. In addition, it is obtained by fractionation, has an average molecular weight of less than 8,000 Daltons (Da), and provides more predictable effects than natural, unfractionated heparin.

Moreover, the safety and efficacy of these have been demonstrated in clinical trials, and it has been observed that it can be used for the prevention and treatment of venous and arterial thromboembolism. Furthermore, the market potential of these has continuously grown owing to their increased use in several countries and potential new indications. Hence, such factors are positively impacting the market. Therefore, it is expected to drive the market growth during the forecast period.

Major Market Challenges

Product recalls are one of the key challenges hindering the market growth. There has been an increase in the number of product recalls over the last few years.  Therefore, such recalls are usually due to the detection of safety issues and product defects. Furthermore, when drug products are known to have possible harmful effects on patients, they may be subjected to a recall.

Moreover, the market has also witnessed certain product recalls, which have posed a challenge to the market. For example, in June 2019, potency concerns provoked B. Braun Medical Inc. to recall 40,176 bags of heparin sodium in dextrose. In addition, the recall affected heparin sodium 25,000 USP units per 250 ml in 5% dextrose injection. Hence, product recalls negatively impact manufacturers in terms of litigation problems and negative publicity, thus hindering market growth during the forecast period.

Buy Now Full Report

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• Product Outlook
  • Low-molecular-weight heparin
  • Others
• Route Of Administration Outlook
  • Subcutaneous injection
  • Intravenous infusion
• Geography Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of the World (ROW)
    • Australia
    • Argentina
    • Brazil

Market Analyst Overview

The market is witnessing substantial growth driven by the rising prevalence of cardiovascular diseases and chronic blood diseases. Heparin, an injectable anticoagulant, plays a crucial role in preventing blood clotting in veins and arteries, especially in patients undergoing medical surgeries or those with blood clotting disorders. With an increasing elderly demographic and the prevalence of conditions such as Coronary Artery Disease (CAD) and Atrial fibrillation, the demand for these is expected to rise. Additionally, initiatives by organizations like the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), along with investments in healthcare infrastructure, are further fueling market growth.

The market is witnessing growth due to factors such as the increasing prevalence of chronic diseases like cardiovascular diseases (CVD), chronic respiratory diseases, and diabetes. Investments in healthcare infrastructure and initiatives to combat fungal infections and counterfeit drugs are also driving market expansion. Heparin, including Low Molecular Weight Heparin (LMWH) and Ultra-low Molecular Weight Heparin (ULMWH), plays a crucial role in preventing conditions such as heart attacks, stroke, and deep vein thrombosis & pulmonary embolism. With a focus on Plasma-derived therapies (PDTs) and advancements in Orthopedic disorders treatment, the market is poised for further growth.

The market is influenced by various factors, including accidents leading to the need for anticoagulant therapy. Understanding patient epidemiology is crucial for determining the demand for these products. The market is also driven by the growing demand for antiplatelet drugs and increasing investment in healthcare infrastructure to address noncommunicable diseases (NCDs). The efficient management of the blood donation system is essential for ensuring an adequate supply of heparin. The use of Intravenous (IV) administration is common for heparin delivery, especially in hospitals & ASCs and clinics. With a rising geriatric population and increasing overall patient population, the demand for these products is expected to grow steadily. The Market is impacted by factors such as the dynamics of the antiplatelet drugs market and investment in healthcare infrastructure. Variants like porcine heparin, bovine heparin, and LMWH (Low Molecular Weight Heparin), including Optimvia, play crucial roles. Bovine sources are also significant in the market.

Heparin Market Scope
Report Coverage	Details
Page number	165
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 7.22%
Market Growth 2024-2028	USD 3.34 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	6.75
Regional analysis	Europe, North America, Asia, and the Rest of the World (ROW)
Performing market contribution	Europe at 34%
Key countries	US, UK, Germany, France, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Aspen Pharmacare Holdings Ltd, B.Braun SE, Baxter International Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, Hebei Changshan Biochemical, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos ROVI S A, LEO Pharma AS, Nanjing Kingfriend Biochemical, Nichi Iko Pharmaceutical Co. Ltd., Novartis AG, Pfizer Inc., Sanofi SA, Shanghai Fosun Pharmaceutical Group Co. Ltd., Shenzhen Techdow Pharmaceutical, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Opocrin SpA
Market dynamics	Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2024 and 2028
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about vendors
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch